Identification and characterisation of new immunoreactive proteins of Chlamydia trachomatis
Abstract number: P1156
Forsbach-Birk V., Pfrepper K.-I., Simnacher U., Soutschek E., Essig A.
Objective: The serological detection of chronic urogenital infections caused by Chlamydia trachomatis is complicated by the lack of known immunoreactive antigens that do not share crossreacting epitopes with other Chlamydia species pathogenic to humans. For that reason we aimed to identify and characterise new so far unidentified immunoreactive antigens of Chlamydia trachomatis.
Methods: Purified elementary bodies were analysed by 2D-PAGE followed by Western blotting with sera from patients with proven pelvic inflammatory disease caused by Chlamydia trachomatis. Unknown antigens being identified by that method were cloned in Escherichia coli and characterised with panels of sera from patients with chronic urogenital infections with Chlamydia trachomatis as well as from healthy blood donors with positive MIF tritres for Chlamydia trachomatis or Chlamydophila pneumoniae.
Results: Besides known immunoreactive antigens like MOMP, OMP2, and HSP60 a number of new immunoreactive antigens of Chlamydia trachomatis were identified by 2D-PAGE and Western blotting with the defined sera. The newly identified antigens were produced recombinantly and proved to be immunoreactive. Their reactivity to the defined serum panels was compared to known immunoreactive antigens. The data revealed a high sensitivity of the newly identified antigens. They showed lower crossreactivitiy to Chlamydophila pneumoniae and a much better discrimination between patients with chronic urogenital infections caused by Chlamydia trachomatis and seropositive but healthy blood donors.
Conclusion: The newly identified antigens need to be further characterised but might be of importance in order to improve current serological approches for the diagnostics of Chlamydia trachomatis infections.
|Session name:||18th European Congress of Clinical Microbiology and Infectious Diseases|
|Back to top|